Compare Herbalife Nutrition Ltd (HLF) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.76 (market cap $1.49B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Herbalife Nutrition Ltd is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HLF | MRVI | |
|---|---|---|
Market Cap | $1.49B | $972.90M |
Volume | 1,708,975 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $9.00 |
52-Week Low | $7.75 | $2.83 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.32B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $14.19, up 4.26% today, with a bullish technical signal and strong analyst consensus. The stock shows attractive valuation with a P/E of 9.11 and P/S of 0.29, supported by a gross profit margin of 77.7%. Recent news includes a $250 million share repurchase program and a planned CEO transition in October 2026. Cash flow trends indicate improving operational cash generation, with 2026 projected net cash flow turning positive at $50 million.
The outlook for HLF is positive, with a consensus price target of $19.00 implying 34% upside. Risks include negative shareholder equity, high debt levels, and mixed quarterly earnings performance. Revenue stability and margin expansion efforts provide a foundation for growth, but investor caution is warranted due to ongoing leadership changes and competitive pressures in the wellness sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
